BioCryst announced the dosing of the first subject in a randomized, placebo-controlled phase 1 clinical trial to evaluate intravenous galidesivir in healthy volunteers. The main goals of this trial are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of galidesivir in healthy subjects. Up to four single-dose cohorts will be evaluated with a total of up to 32 volunteers participating. The galidesivir development program is substantially funded with federal funds from the National Institute of Allergy and Infectious Diseases, or NIAID, part of the National Institutes of Health, and by the Biomedical Advanced Research and Development Authority.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.